Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Registration Number
- NCT00831233
- Lead Sponsor
- Ferring Pharmaceuticals
- Brief Summary
The purpose of this trial was to see how well a new trial drug (degarelix) worked on lower urinary tract symptoms (also known as LUTS) in prostate cancer patients as compared to how a standard drug hormonal treatment worked on the same symptoms. The advancement/worsening of prostate cancer may be associated with LUTS and the symptoms may impact the ability to urinate normally and thereby the quality of life for these patients.
Patients were randomly selected (like flipping a coin) to receive either degarelix or standard hormone therapy (combination of goserelin and bicalutamide) for a 3 month treatment period. During this period the relief of urinary symptoms was evaluated via a questionnaire filled in by patients and addressing the severity and frequency of their symptoms.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 42
- Patient has given written informed consent before any trial-related activity is performed
- Has a confirmed prostate cancer in which this type of treatment is needed.
- Previous treatment for prostate cancer
- Previous trans-urethral resection of the prostate
- Current use of 5-alpha reductase inhibitor or α-adrenoceptor antagonist.
- Patients in need of external beam radiotherapy to be started at the same time as hormone therapy
- Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)
- History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
- Hypersensitivity towards any component of the investigational product
- Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.
- Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Goserelin (3.6 mg) + bicalutamide (50 mg) Goserelin Goserelin (3.6 mg) + bicalutamide (50 mg) Degarelix 240 mg/80 mg Degarelix Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL) Goserelin (3.6 mg) + bicalutamide (50 mg) Bicalutamide Goserelin (3.6 mg) + bicalutamide (50 mg)
- Primary Outcome Measures
Name Time Method Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 After treatment of 12 weeks compared to Baseline The IPSS is a tool commonly used to assess the severity of lower urinary tract symptoms (LUTS), and to monitor the progress of the disease once treatment has been initiated. The participant completes a questionnaire containing 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5. The total score is then classified according to the following scale: 0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; and 20 to 35 = severely symptomatic.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Maximum Urine Flow (Qmax) at Each Visit After treatment of 4, 8 and 12 weeks compared to Baseline Uroflowmetry was used to quantify the maximum urine flow (Qmax; mL/sec)
Change From Baseline in Residual Volume (Vresidual) at Each Visit After treatment of 4, 8 and 12 weeks compared to Baseline Uroflowmetry was used to quantify the residual volume (Vresidual; mL)
Change From Baseline in Total IPSS at Weeks 4 and 8 After treatment of 4 and 8 weeks compared to Baseline The IPSS is a tool commonly used to assess the severity of lower urinary tract symptoms (LUTS), and to monitor the progress of the disease once treatment has been initiated. The participant completes a questionnaire containing 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5. The total score is then classified according to the following scale: 0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; and 20 to 35 = severely symptomatic.
Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 After 12 weeks treatment compared to Baseline TRUS is a method of measuring the size of the prostate.
Number of Participants With Testosterone <=0.5 Nanograms/Milliliter at Each Visit After treatment of 4, 8 and 12 weeks compared to Baseline Percentage Change From Baseline in Prostate-specific Antigen (PSA) Concentration at Each Visit After treatment of 4, 8 and 12 weeks compared to Baseline Change From Baseline in Quality of Life (QoL) Related to Urinary Symptoms at Each Visit After treatment of 4, 8 and 12 weeks compared to Baseline The IPSS questionnaire included an additional single question to assess the participant's QoL in relation to his urinary symptoms. The question was: 'If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?' The possible answers to this question ranged from 'delighted' (a score of '0') to 'terrible' (a score of '6'). The figures in the tables present the change (ie decrease) in IPSS QoL score, i.e. the bigger the decrease the better QoL.
Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables Baseline to 12 weeks of treatment The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) levels of safety laboratory variables. Only the laboratory variables that had at least on participant with one abnormal value are presented, many more variables were included in the trial.
Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight Baseline to 12 weeks of treatment This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value.
Trial Locations
- Locations (32)
Fundación Puigvert
🇪🇸Barcelona, Spain
Fundacion Hospital Alcorcón
🇪🇸Alcorcon, Spain
Hospital de Basurto
🇪🇸Bilbao (Bizkaia), Spain
Urologische Gemeinschaftspraxis
🇩🇪Hamburg, Germany
Gemeinschaftspraxis
🇩🇪Köln, Germany
Klinikum Offenbach GmbH
🇩🇪Offenbach, Germany
Falkirk and District Royal Infirmary
🇬🇧Falkirk, United Kingdom
Hospital Santiago de Compostela
🇪🇸Santiago de Compostela, Spain
Facharztpraxis für Urologie
🇩🇪Bamberg, Germany
Euromed Clinic
🇩🇪Fürth, Germany
VITURO Gesellschaft für Klinische Studien
🇩🇪Leipzig, Germany
Urologische Klinik Planegg
🇩🇪Planegg, Germany
Hospital Universitario Principe de Asturias
🇪🇸Alcalá de Henares-Madrid, Spain
Complejo Hospitalario Universitario A Coruña
🇪🇸Coruña, Spain
Hospital Clinico Universitario S. Carlos
🇪🇸Madrid, Spain
Hospital universitario Ramón y Cajal
🇪🇸Madrid, Spain
Hospital Universitario Central de Asturias
🇪🇸Oviedo, Spain
Hospital Xeral de Vigo
🇪🇸Vigo, Spain
Hospital Virgen Macarena
🇪🇸Sevilla, Spain
United Bristol Healthcare NHSTrust Bristol Royal Infirmary
🇬🇧Bristol, United Kingdom
Southern General Hospital
🇬🇧Glasgow, United Kingdom
King's College Hospital
🇬🇧London, United Kingdom
Whipps Cross University Hospital
🇬🇧London, United Kingdom
The Royal Free Hospital
🇬🇧London, United Kingdom
Derriford Hospital
🇬🇧Plymouth, United Kingdom
Royal Hallamshire Hospital, Sheffield South
🇬🇧Sheffield, United Kingdom
Sunderland Royal Hospital
🇬🇧Sunderland, United Kingdom
Hospital Universitario Puerta de Hierro
🇪🇸Majadahonda, Madrid, Spain
Universitätsklinikum Dresden
🇩🇪Dresden, Germany
Wuppertaler Gemeinschaftspraxis
🇩🇪Wuppertal, Germany
Hospital Manacor
🇪🇸Manacor, Spain
Castle Hill Hospital
🇬🇧Hull, United Kingdom